Related Experiment Video

Updated: Jun 5, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Targeting EGFR in bilio-pancreatic and liver carcinoma

Maria Elisabetta Fratto1, Daniele Santini, Bruno Vincenzi

  • 1Medical Oncology, University Campus Bio-Medico, Rome.

Frontiers in Bioscience (Scholar Edition)
|January 4, 2011
PubMed

Insights

Epidermal growth factor receptor (EGFR) targeted therapies show promise in digestive cancers. Patient selection using biomarkers is crucial for effective treatment with EGFR inhibitors and antibodies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gastroenterology

Background:

  • Epidermal growth factor receptor (EGFR) plays a critical role in tumorigenesis across various cancer types.
  • EGFR-targeted agents, including monoclonal antibodies and tyrosine kinase inhibitors, have been developed for cancer treatment.

Purpose of the Study:

  • To review the preclinical rationale and clinical trial data for anti-EGFR agents in non-colorectal digestive cancers.
  • To evaluate the efficacy of EGFR-targeted agents in monotherapy and combination treatments.
  • To highlight the importance of patient selection using biomarkers for treatment success.

Main Methods:

  • Review of preclinical studies on EGFR's role in tumorigenesis.
  • Analysis of key clinical trials evaluating EGFR-targeted agents (monoclonal antibodies and TKIs).
  • Assessment of combination therapies involving EGFR inhibitors and other agents.

Main Results:

  • EGFR-targeted agents demonstrate potential activity in non-colorectal digestive cancers.
  • Both monoclonal antibodies (cetuximab, panitumumab) and TKIs (gefitinib, erlotinib) have been investigated.
  • Combination therapies may enhance treatment efficacy.

Conclusions:

  • EGFR-targeted therapies are a significant area of investigation for digestive cancers.
  • Biomarker-driven patient selection is essential for optimizing the use of these agents.
  • Further research and clinical trials are warranted to refine treatment strategies.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...